切换至 "中华医学电子期刊资源库"
高级检索
中华介入放射学电子杂志

中华介入放射学电子杂志 ›› 2016, Vol. 04 ›› Issue (01) : 1 -3. doi: 10.3877/cma.j.issn.2095-5782.2016.01.001

所属专题： 文献； 指南共识；

指南与共识

注射用洛铂在原发性肝癌TACE治疗中的专家共识（2016版）
中国医师协会介入医师分会   
  • 收稿日期:2016-01-20 出版日期:2016-02-01

Guidelines and Consensus Expert consensus on Lobaplatin for injection in the TACE treatment of patients with primary hepatic carcinoma(2016)

Interventional Physicians Branch of Chinese Physicians' Association   

  • Received:2016-01-20 Published:2016-02-01
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

中国医师协会介入医师分会. 注射用洛铂在原发性肝癌TACE治疗中的专家共识（2016版）[J]. 中华介入放射学电子杂志, 2016, 04(01): 1-3.

Interventional Physicians Branch of Chinese Physicians' Association. Guidelines and Consensus Expert consensus on Lobaplatin for injection in the TACE treatment of patients with primary hepatic carcinoma(2016)[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2016, 04(01): 1-3.

1
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer，2015，136(5):E359-386. doi: 10.1002/ijc.29210.
2
Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013[J]. JAMA Oncol，2015, 1(4):505-527. doi: 10.1001/jamaoncol.2015.0735.
3
McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015[J]. Adv Nutr, 2016, 7(2):418-419. doi: 10.3945/an.116.012211.
4
McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability[J]. Clin Liver Dis, 2015, 19(2):223-238. doi: 10.1016/j.cld.2015.01.001.
5
Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?[J]. J Hepatol, 2005, 43(4):584-589.
6
Pompili M, Saviano A, de Matthaeis N, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey[J]. J Hepatol, 2013, 59(1):89-97. doi: 10.1016/j.jhep.2013.03.009.
7
Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319):1734-1739.
8
Liapi E, Geschwind JF. Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma[J]. Liver Cancer, 2012, 1(3-4):201-215. doi: 10.1159/000343835.
9
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology, 2003, 37(2):429-442.
10
Lo CM, Ngan H, Tso WK,et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]. Hepatology, 2002, 35(5):1164-1171.
11
Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis[J]. Liver Int, 2010, 30(5):741-749. doi: 10.1111/j.1478-3231.2010.02221.x.
12
Marelli L, Stigliano R, Triantos C, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies[J]. Cancer Treat Rev, 2006, 32(8):594-606.
13
Bruix J, Sherman M. Management of hepatocellular carcinoma: An update[J]. Hepatology, 2011, 53(3):1020-1022 doi: 10.1002/hep.24199.
14
Si Y, Hu X, Du H, et al. Transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a retrospective study of a 5-year experience in a single institution[J]. Hepatogastroenterology, 2013, 60(126):1405-1408. doi: 10.5754/hge121310.
15
Saris CP, van de Vaart PJ, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells[J]. Carcinogenesis, 1996, 17(12):2763-2769.
16
Harstrick A, Bokemeyer C, Scharnofkse M, et al. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and-resistant human testicular, ovarian, and gastric carcinoma cell lines[J]. Cancer Chemother Pharmacol,1993, 33(1):43-47.
17
McKeage MJ. Lobaplatin: a new antitumour platinum drug[J]. Expert Opin Investig Drugs, 2001, 10(1):119-128.
18
Wu Q, Qin SK, Teng FM, et al. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells[J]. J Hematol Oncol, 2010, 3:43. doi: 10.1186/1756-8722-3-43.
19
钱军, 秦叔逵, 杨爱珍, 等. 不同铂类药物对人肝癌细胞株抑制作用的实验研究[J]. 临床肿瘤学杂志, 2009, 14(5): 414-417. doi:10.3969/j.issn.1009-0460.2009.05.007.
20
Wang Y, Zheng WL, Ma WL. Lobaplatin inhibits the proliferation of hepatollular carcinoma through p53 apoptosis axis[J]. Hepat Mon, 2012, 12(10 HCC):e6024. doi: 10.5812/hepatmon.
21
石明, 陈继安, 林小军, 等. 肝动脉栓塞化疗不同化疗方案治疗不可切除肝癌的前瞻性随机对照研究[J]. 中国肿瘤临床, 2009, 36(1): 9-13. doi:10.3969/j.issn.1009-0460.2009.05.007.
22
Zhou B, Shan H, Zhu KS, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation[J]. J Vasc Interv Radiol, 2010, 21(3):333-338. doi: 10.1016/j.jvir.2009.11.006.
23
Wang N, Lv YZ, Xu AH, et al. Application of lobaplatin in trans-catheter arterial chemoembolization for primary hepatic carcinoma[J]. Asian Pac J Cancer Prev, 2014, 15(2):647-650.
24
张鹏, 李晓冰, 任虎虎, 等. 经皮肝动脉栓塞化疗联合洛铂热灌注化疗治疗不能手术切除的肝细胞癌的近期疗效观察[J].中国肿瘤临床，2013, 40(5): 284-286. doi：10.3969/j.issn.1000-8179.2013.05.010.
25
中华医学会中华放射学杂志编委会介入放射学组. 肝癌介入治疗规范化条例(草案)[J]. 中华放射学杂志，2001,12(35): 887-891.
26
王建华，周康荣. 肝癌综合性介入治疗规范化方案(草案)[J]. 临床放射学杂志，2002,21(7): 497-500.
No related articles found!
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号